InvestorsHub Logo
Followers 48
Posts 12044
Boards Moderated 0
Alias Born 09/12/2017

Re: bigboard post# 78074

Thursday, 05/14/2020 3:29:10 PM

Thursday, May 14, 2020 3:29:10 PM

Post# of 233151
My OPINION is the SEC might be taking a hard look at Cytodyn/NP.

If it were me, the first person I'd interview is the fired former CFO. If there are any proverbial skeletons buried, he'd likely know where they are.

Seems the SEC could easily suspend CYDY on the adequacy and accuracy of this press release in the marketplace alone:

CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients
https://www.globenewswire.com/news-release/2020/04/27/2022519/0/en/CytoDyn-Submits-Completed-Biologics-License-Application-BLA-to-the-FDA-for-Leronlimab-as-a-Combination-Therapy-for-Highly-Treatment-Experienced-HIV-Patients.html

Which makes me think (and I could be wrong) the SEC may bring charges. If there's any one thing that gets the SEC's ears to stand at attention is money. Well, The combined stock sales ($19.6M) of the CEO and CMO probably accomplished that litmus test.






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News